The many effective therapeutic options available in the management of rectal cancer have led to greater effort toward pretreatment staging, risk stratification, and individualized treatment. More vigorous treatments carry potentially increased morbidity, longer disability, higher costs, and lasting changes in quality of life. Multimodality therapy is commonly used for “bad” (locally advanced) or “ugly” (metastatic) rectal cancers, but which ones are “good” (early) enough to be curable by local excision? This question is addressed by Dr Salinas and his colleagues.
Pricolo VE. Rectal Cancer: The Good, the Bad, and the UglyComment on “Determining the Need for Radical Surgery in Patients with T1 Rectal Cancer ”. Arch Surg. 2011;146(5):544. doi:10.1001/archsurg.2011.71